Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Clinical trial NCT03600090 · COMPLETED
Trial details
- NCT number
- NCT03600090
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-16
- Primary completion
- 2021-12-25
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.